Published Date: 31-Jan-2023
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report, published by KBV research, The Global Body Fluid Collection And Diagnostics Market size is expected to reach $42.2 billion by 2028, rising at a market growth of 6.9% CAGR during the forecast period.
The Instruments segment is showcasing a CAGR of 7.2% during (2022 - 2028). The laboratories have deployed analyzer-based body fluid analysis for cell counting to provide the best quality insights and eventually replace the manual cell counting process. Furthermore, it will be very helpful to the labs having large sample loads on routine basis. Market in this segment in predicted to grow as a result of the rising old aged population requiring continue diagnosis and care.
The Polymerase Chain Reaction (PCR) segment acquired maximum revenue share in the Global Body Fluid Collection and Diagnostics Market by Technology in 2021 thereby, achieving a market value of $25 billion by 2028. Body fluid DNA sequencing is an intra-operative method for infectious disease and genetic disorder treatment. T oligo-primed polymerase chain reaction is an advanced technique that can be used for small DNA fragment amplification in body fluid.
The Urine segment has shown the growth rate of 7.1% during (2022 - 2028). To identify and provide treatment for the disease, medical tests are becoming an essential tool. Collection of urine is done for the metabolic identification of proteinuria, urinary stone disease, renal function prediction, and others. The testing is done in an outpatient environment. The researcher has stated that they are carrying out new tests which can help in the early treatment of chronic kidney diseases.
The Diagnostics & Monitoring segment is leading the Global Body Fluid Collection And Diagnostics Market by Application in 2021 thereby, achieving a market value of $18.4 billion by 2028. Low cost, less invasiveness, and fast sample collection & diagnosis are benefits of body fluid diagnostics for disease diagnosis and monitoring. Body fluid diagnostics is now considered to be one of the most appropriate methods for the premature diagnosis, monitoring, management, and analysis of the early reaction to chronic diseases and also for determining the possible pathogenesis of such abnormalities.
The North America market dominated the Global Body Fluid Collection And Diagnostics Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $17.5 billion by 2028. The Europe market is exhibiting a CAGR of 6.5% during (2022 - 2028). Additionally, The Asia Pacific market would display a CAGR of 7.4% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/body-fluid-collection-and-diagnostics-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., Qiagen N.V., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Laboratory Corporation of America Holdings, Biocept, Inc., MDxHealth SA, and Guardant Health, Inc.
By Sample Type
Unique Offerings from KBV Research
North America Body Fluid Collection And Diagnostics Market size & Opportunities 2022-2028
Europe Body Fluid Collection And Diagnostics Market & Growth Forecast 2022-2028
Asia Pacific Body Fluid Collection And Diagnostics Market Share & Industry Outlook to 2028
LAMEA Body Fluid Collection And Diagnostics Market Growth, Trends & Forecasts 2022-2028